Soares Marc A, Ezeamuzie Obinna C, Ham Maria J, Duckworth April M, Rabbani Piul S, Saadeh Pierre B, Ceradini Daniel J
New York, N.Y. From the New York University Department of Plastic Surgery Laboratories, New York University Langone Medical Center.
Plast Reconstr Surg. 2015 Feb;135(2):488-499. doi: 10.1097/PRS.0000000000000909.
Fat grafting is limited by unpredictable long-term graft retention. The authors postulate that injury to the donor-derived microvasculature during harvest and subsequent ischemia may account for this clinical variability. They examined the use of the U.S. Food and Drug Administration-approved phosphodiesterase-5 inhibitor sildenafil citrate to protect graft microvasculature and its role in revascularization and survival.
Inguinal fat of donor Tie2/LacZ mice was infiltrated with sildenafil or saline, harvested, and transplanted onto the dorsa of recipient FVB mice. Additional donor mice were perfused with intraarterial trypsin to inactivate the fat graft microvasculature before harvest and transplantation. Differences in graft revascularization, perfusion, volume of retention, and biochemical changes were assessed.
Surviving fat grafts were characterized by exclusively donor-derived vasculature inosculating with the recipient circulation at the graft periphery. Inactivation of donor-derived microvasculature decreased early graft perfusion and led to nearly total graft loss by 8 weeks. Sildenafil attenuated vascular ischemic injury, consistent with reductions in VCAM-1 and SDF1α expression at 48 hours and 4-fold increases in microvasculature survival by 2 weeks over controls. Compared with controls, targeted sildenafil treatment improved early graft perfusion, doubled graft retention at 12 weeks (83 percent versus 39 percent; p < 0.05), ultimately retaining 64 percent of the original graft volume by 24 weeks (compared to 4 percent; p < 0.05) with superior histologic features.
Fat graft vascularization is critically dependent on maintenance of the donor microvasculature. Sildenafil protects the donor microvasculature during transfer and revascularization, increasing long-term volume retention. These data demonstrate a rapidly translatable method of increasing predictability and durability of fat grafting in clinical practice.
脂肪移植受不可预测的长期移植留存率限制。作者推测,采集过程中供体来源的微血管损伤及随后的缺血可能是造成这种临床差异的原因。他们研究了美国食品药品监督管理局批准的磷酸二酯酶-5抑制剂枸橼酸西地那非对移植微血管的保护作用及其在血管再生和存活中的作用。
将西地那非或生理盐水注入供体Tie2/LacZ小鼠的腹股沟脂肪,采集后移植到受体FVB小鼠的背部。另外,在采集和移植前,对供体小鼠进行动脉内胰蛋白酶灌注,使脂肪移植微血管失活。评估移植血管再生、灌注、留存体积和生化变化的差异。
存活的脂肪移植的特征是,仅供体来源的血管在移植周边与受体循环吻合。供体来源的微血管失活会降低早期移植灌注,并导致8周时几乎完全的移植丢失。西地那非减轻了血管缺血损伤,与48小时时VCAM-1和SDF1α表达降低以及2周时微血管存活率比对照组增加4倍一致。与对照组相比,靶向西地那非治疗改善了早期移植灌注,12周时移植留存率翻倍(83%对39%;p<0.05),到24周时最终保留了原始移植体积的64%(相比之下为4%;p<0.05),组织学特征更佳。
脂肪移植血管化严重依赖于供体微血管的维持。西地那非在转移和血管再生过程中保护供体微血管,增加长期体积留存。这些数据证明了一种可快速转化的方法,可提高临床实践中脂肪移植的可预测性和耐久性。